Belgium· BE-AMP-SAM598666-00
Breyanzi
A lisocabtagene maraleucel product containing lisocabtagene maraleucel, registered in Belgium by Bristol-Myers Squibb Pharma. The same ATC class is registered in 12 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Lisocabtagene maraleucel is registered in 12 of 19 countries.
Countries holding a registration under ATC L01XL08 (lisocabtagene maraleucel), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Lisocabtagene maraleucel · ATC L01XL08
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Lisocabtagene Maraleucel
- Manufacturer
- Bristol-Myers Squibb Pharma
- Country
- Belgium (BE)
- ATC code
- L01XL08
- ATC class
- Lisocabtagene maraleucel
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb7750136
- be_apb4522785
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
37 interactions on record for lisocabtagene maraleucel.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lisocabtagene maraleucel · interactions on record
37 records
- 21 severe
- 16 moderate
Most severe, free to view
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- NatalizumabL04AA23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lisocabtagene maraleucel in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsBreyanzi >= 5.1 x 10^6 cellen [CD4 component], suspensie voor injectieCelgene Europe B.V.
- CzechiaBREYANZIBristol-Myers Squibb Pharma EEIG, Dublin
- SpainBREYANZI 1,1-70 × 10E6 CELULAS/ML / 1,1-70 × 10E6 CELULAS/ML DISPERSION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandBreyanziBristol-Myers Squibb Pharma EEIG
- FranceBREYANZI 1,1 à 70 × 1 000 000 cellules/ml / 1,1 à 70 × 1 000 000 cellules/ml, dispersion pour perfusionBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- United KingdomBreyanzi 1.1million-70million cells/ml / 1.1million-70million cells/ml dispersion for infusion vialsBristol-Myers Squibb Pharmaceuticals Ltd
- IrelandBreyanzi 1.1-70 x 10^6 cells/mL/1.1-70 x 10^6 cells/mL dispersion for infusionCelgene Europe B.V.
- IcelandBreyanziBristol-Myers Squibb Pharma EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Breyanzi
- Liechtenstein · Breyanzi
- Norway · Breyanzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/93a74246-632d-4e24-a99c-9bddd82411b8 GET /v1/drugs/93a74246-632d-4e24-a99c-9bddd82411b8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dispersion for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Breyanzi",
"name_fr": "Breyanzi",
"name_nl": "Breyanzi",
"amp_code": "SAM598666-00",
"strengths": [
"0.0760",
"2.7170"
],
"pack_count": 1,
"substances": [
"Lisocabtagene Maraleucel",
"Dimethyl Sulfoxide",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Lisocabtagene Maraleucel",
"authorisation_numbers": [
"EU/1/22/1631/001"
]
}See everything about lisocabtagene maraleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.